Endocrine Abstracts

Background: Symptom management is a cornerstone of clinical care, particularly for patients with cancer. However, often patient’s symptoms go undetected by health care providers between clinic visits. Mobile health applications are increasingly used in oncological care to support cancer patients.Aims: To develop a patient focussed mobile application to enable patients to track symptoms, record quality of life, communicate with their clinical teams a...

Introduction: Gastric NENs are increasingly being diagnosed at endoscopy. The majority of these are type 1 gastric NEN. However, around 10–20% can be type 3 or type 4 Gastric NENs.Methods: A retrospective review performed of 54 patients with gastric NENs referred to a tertiary centre during 2014 to 2019.Results: Of the 54 cases referred, 45 were type 1 gastric NENs and the 9 were type 3 Gastric NENs. Of the 45 type 1 gastric N...

Introduction: Perioperative mortality of patients who undergo heart valve surgery for carcinoid heart valve disease (CHVD) has been observed to be high (5–10%). We investigated whether peptide receptor radiotherapy (PRRT) with Lutetium-177 Dotatate can be used safely in patients with neuroendocrine neoplasms (NEN) and CHVD and if there is an associated survival advantage by reducing overall exposure of the valves to high doses of vasoactive peptides.<p class="abstext"...

Digital technology has an important role in the monitoring and management of long term conditions. The purpose of this study was to evaluate the feasibility of using PROMS to monitor symptoms, via a disease specific mobile application. Secondary endpoints included QoL and patient engagement. In addition, we reviewed the total number of symptoms reports and time required for patients to complete and submit these.Methods: Unmet patient nee...

Introduction: The incidence and prevalence of GEP-NENs is rising worldwide. NENs represent the group off well differentiated neuroendocrine tumours (NET) and poorly differentiated neuroendocrine carcinoma (NEC). NETs can be divided into grade 1 (G1), grade 2 (G2) and grade 3 (G3) based on histological parameters. There exist several studies regarding survival data but these are mainly based on national databases.Aim: To describe the real world overall su...

Background: The safety and efficacy of telotristat ethyl (TE) in patients (pts) with metastatic neuroendocrine tumors (NETs) and carcinoid syndrome (CS) not adequately controlled with somatostatin analogs (SSAs) have been demonstrated. TE-treated pts showed significantly greater reductions in bowel movement (BM) frequency and more presented with durable response than placebo (PBO)-treated pts. These post-hoc analyses examined the relationship between improvements in symptoms a...

Background: Type III gastric neuroendocrine neoplasms (g-NEN) are usually lesions of higher grade and often associated with loco-regional and distant metastases. Guidelines recommend partial or total gastrectomy with local lymph node resection. Data for less-extensive resections are limited.Aim: To assess whether advanced endoscopic excision [Endoscopic Mucosal Resection (EMR) or Endoscopic Submucosal Dissection (ESD)] or localized surgical approach (wed...

Background: Small pancreatic neuroendocrine tumours (PNETs) present a management dilemma because of their uncertain natural history. Some clinicians believe that lesions <2 cm are indolent and can be managed with surveillance. By contrast, the most recent WHO classification system regards all PNETs as potentially malignant.Aim: To assess the malignant behaviour of small PNETs in a large, retrospective, multicentre patient cohort.<p class="abstext...

Background: Everolimus, a mammalian target of rapamycin inhibitor, is licensed for use in adult pts with advanced well-differentiated pNETs in the UK. Limited Health-Related Quality-of-Life (HrQOL) data are available for everolimus therapy in these pts.Methods: This prospective study assessed changes in HrQoL (by monthly patient-reported EORTC QLQ-C30, -G.I.NET21 and EQ-5D questionnaires), in pts with pNETs during the first 6 months (mo) of treatment wit...

Prolactin (PRL) is a peptide hormone produced by the anterior pituitary gland and it is commonly known for its lactogenic and mammotrophic effects. In humans and primates, prolactin is also expressed in extra-pituitary sites where it is associated with numerous biological functions, but its spectrum of expression varies in different species.Hyperprolactinemia-induced osteoporosis is believed to be mediated by hypogonadism, but the expression of the prola...